Research Analysts Issue Forecasts for APLS Q1 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Wedbush decreased their Q1 2025 EPS estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.46) per share for the quarter, down from their previous forecast of ($0.43). Wedbush has a “Neutral” rating and a $29.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.59) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $2.05 EPS and FY2029 earnings at $3.50 EPS.

APLS has been the topic of a number of other research reports. Royal Bank of Canada lowered their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a report on Monday, March 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Scotiabank lifted their target price on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research report on Wednesday, April 2nd. HC Wainwright reissued a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group reduced their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $45.59.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $18.20 on Friday. The stock has a market cap of $2.28 billion, a PE ratio of -8.97 and a beta of 0.85. Apellis Pharmaceuticals has a fifty-two week low of $17.49 and a fifty-two week high of $50.98. The firm’s fifty day simple moving average is $23.93 and its 200-day simple moving average is $28.07. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.73) earnings per share.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its position in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after acquiring an additional 735,160 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Apellis Pharmaceuticals by 9.4% in the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company’s stock valued at $691,000 after purchasing an additional 1,864 shares in the last quarter. KBC Group NV raised its position in Apellis Pharmaceuticals by 3,862.3% in the fourth quarter. KBC Group NV now owns 104,287 shares of the company’s stock valued at $3,328,000 after purchasing an additional 101,655 shares during the period. Entropy Technologies LP acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth about $445,000. Finally, Barclays PLC boosted its position in shares of Apellis Pharmaceuticals by 18.0% in the third quarter. Barclays PLC now owns 255,897 shares of the company’s stock worth $7,381,000 after buying an additional 39,019 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 2,824 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total transaction of $83,364.48. Following the completion of the sale, the chief executive officer now owns 415,695 shares of the company’s stock, valued at approximately $12,271,316.40. The trade was a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel David O. Watson sold 5,569 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 36,011 shares of company stock worth $1,059,969. 6.80% of the stock is owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).